PL2865751T3 - Stabilizowana alfa-galaktozydaza i jej zastosowania - Google Patents

Stabilizowana alfa-galaktozydaza i jej zastosowania

Info

Publication number
PL2865751T3
PL2865751T3 PL14195875T PL14195875T PL2865751T3 PL 2865751 T3 PL2865751 T3 PL 2865751T3 PL 14195875 T PL14195875 T PL 14195875T PL 14195875 T PL14195875 T PL 14195875T PL 2865751 T3 PL2865751 T3 PL 2865751T3
Authority
PL
Poland
Prior art keywords
galactosidase
stabilized alpha
stabilized
alpha
Prior art date
Application number
PL14195875T
Other languages
English (en)
Inventor
Avidor Shulman
Ilya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of PL2865751T3 publication Critical patent/PL2865751T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
PL14195875T 2010-03-02 2011-03-02 Stabilizowana alfa-galaktozydaza i jej zastosowania PL2865751T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
PL2865751T3 true PL2865751T3 (pl) 2017-03-31

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14195875T PL2865751T3 (pl) 2010-03-02 2011-03-02 Stabilizowana alfa-galaktozydaza i jej zastosowania

Country Status (24)

Country Link
EP (3) EP3088514B1 (pl)
JP (2) JP5758920B2 (pl)
KR (1) KR101928403B1 (pl)
CN (1) CN102933707B (pl)
AU (1) AU2011222452B2 (pl)
BR (2) BR112012022029B1 (pl)
CA (1) CA2791461C (pl)
DK (1) DK2865751T3 (pl)
ES (2) ES2708843T3 (pl)
FI (1) FIC20230032I1 (pl)
HK (1) HK1180720A1 (pl)
HR (1) HRP20200428T1 (pl)
HU (2) HUE030959T2 (pl)
IL (2) IL221741A (pl)
IN (1) IN2012MN02262A (pl)
NL (1) NL301249I2 (pl)
NO (1) NO2023041I1 (pl)
NZ (2) NZ602317A (pl)
PL (1) PL2865751T3 (pl)
RU (1) RU2604795C2 (pl)
SG (2) SG10201502609QA (pl)
SI (1) SI2865751T1 (pl)
WO (1) WO2011107990A1 (pl)
ZA (1) ZA201206725B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
HUE030959T2 (en) * 2010-03-02 2017-06-28 Protalix Ltd Stabilized alpha-galactosidase and its uses
EP2665814B1 (en) * 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
DK3237621T3 (da) * 2014-12-22 2023-06-19 Codexis Inc Varianter af human alpha-galactosidase
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
CN107429257B (zh) 2015-03-17 2022-02-15 艾丽法有限责任公司 糖基化溶酶体蛋白、生产方法和用途
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
BR112019013920A2 (pt) * 2017-01-05 2020-02-04 Protalix Ltd método para tratar doença de fabry, e, forma unitária de dosagem.
CN110651043A (zh) * 2017-06-07 2020-01-03 天野酶制品株式会社 乳糖酶原料粉末和乳糖酶制剂
EA202191735A1 (ru) 2018-12-20 2021-11-24 Кодексис, Инк. Варианты альфа-галактозидазы человека
JP2023548496A (ja) 2020-11-03 2023-11-17 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DE69839563D1 (de) * 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
BRPI9917760B8 (pt) * 1998-08-06 2021-05-25 Univ Duke método para isolar uma forma tetramérica de uricase a partir de uma solução de uricase purificada
US7270972B1 (en) 1999-04-02 2007-09-18 Ajinomoto Co., Inc. Process for producing subunit peptide originating in polymer protein
AU2003235988A1 (en) 2002-05-15 2003-12-02 Agricultural Research Organization, The Volcani Center Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
JP4368925B2 (ja) * 2005-11-18 2009-11-18 財団法人 東京都医学研究機構 基質特異性を変換した新規高機能酵素
US20100144008A1 (en) 2006-12-21 2010-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
EP2192924B1 (en) 2007-08-20 2017-10-11 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
HUE030959T2 (en) * 2010-03-02 2017-06-28 Protalix Ltd Stabilized alpha-galactosidase and its uses

Also Published As

Publication number Publication date
EP3088514A1 (en) 2016-11-02
IL253249B (en) 2020-08-31
RU2604795C2 (ru) 2016-12-10
HK1180720A1 (en) 2013-10-25
HRP20200428T1 (hr) 2020-06-12
CA2791461C (en) 2019-10-22
SI2865751T1 (sl) 2017-01-31
ZA201206725B (en) 2013-06-26
CN102933707B (zh) 2015-09-30
CN102933707A (zh) 2013-02-13
BR112012022029A2 (pt) 2021-05-18
AU2011222452B2 (en) 2015-09-03
EP2865751A1 (en) 2015-04-29
IL221741A (en) 2017-07-31
HUE030959T2 (en) 2017-06-28
IL253249A (en) 2019-08-29
BR112012022029B1 (pt) 2022-10-11
KR101928403B1 (ko) 2018-12-14
EP2542675B1 (en) 2014-12-17
RU2012141651A (ru) 2014-04-10
SG10201502609QA (en) 2015-05-28
FIC20230032I1 (fi) 2023-11-02
IN2012MN02262A (pl) 2015-06-12
NL301249I2 (nl) 2023-12-14
NZ602317A (en) 2014-04-30
NO2023041I1 (no) 2023-11-01
DK2865751T3 (en) 2017-01-09
JP2013520986A (ja) 2013-06-10
ES2708843T3 (es) 2019-04-11
WO2011107990A1 (en) 2011-09-09
NL301249I1 (pl) 2023-11-08
SG183558A1 (en) 2012-10-30
EP2865751B1 (en) 2016-09-14
EP2542675A1 (en) 2013-01-09
JP5758920B2 (ja) 2015-08-05
EP3088514B1 (en) 2018-11-28
ES2606532T3 (es) 2017-03-24
CA2791461A1 (en) 2011-09-09
BR122014021216A2 (pt) 2021-06-01
KR20130056216A (ko) 2013-05-29
JP5871999B2 (ja) 2016-03-01
HUS2300038I1 (hu) 2023-11-28
JP2014237694A (ja) 2014-12-18
AU2011222452A1 (en) 2012-09-27
NZ623294A (en) 2015-10-30

Similar Documents

Publication Publication Date Title
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HK1206004A1 (en) Ingenol-3-acylates iii and ingenol-3-carbamates -3- iii -3-
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
GB201012175D0 (en) Procedure and mechanisms
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
ZA201208173B (en) Peptices and their use
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
IL229844B (en) Anti-psgl-1 antibodies and their use
EP2701730A4 (en) MFG-E8 AND USES THEREOF
EP2558137A4 (en) METHODS AND COMBINATION
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
EP2547464A4 (en) ARRANGEMENT AND VENTILATION ARRANGEMENT
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201001384D0 (en) Light-fitting and associated methods
GB201119443D0 (en) GoWinging Concept and patent
GB201014319D0 (en) Compounds and uses thereof